Argenx
ARGX
#408
Rank
HK$444.04 B
Marketcap
HK$7,130
Share price
-0.63%
Change (1 day)
46.57%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

EPS for Argenx (ARGX)

EPS in 2025 (TTM): HK$68.96

According to Argenx 's latest financial reports the company's current EPS (TTM) is HK$69.05. In 2024 the company made an earnings per share (EPS) of HK$108.36 an increase over its 2023 EPS that were of -HK$40.17.

EPS history for Argenx from 2011 to 2025

Annual EPS

Year EPS Change
2025 (TTM)HK$68.96-36.36%
2024HK$108.36-369.77%
2023-HK$40.17-60.46%
2022-HK$101.5963.33%
2021-HK$62.20-40.37%
2020-HK$104.31183.47%
2019-HK$36.80123.09%
2018-HK$16.4954.93%
2017-HK$10.6514.07%
2016-HK$9.3313.05%
2015-HK$8.26-36.34%
2014-HK$12.97209.04%
2013-HK$4.20-33.99%
2012-HK$6.36185.59%
2011-HK$2.23